Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme

Sylvie Bastuji‐Garin · Archives of Dermatology · 1993 · 1.6K citations

Medicine, Dermatology, Pathology +13

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 418 citations

Medicine, Oncology, Pharmacology +14

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy

Sonja Ständer, Dorothee Siepmann, Ilka Herrgott et al. · PLoS ONE · 2010 · 290 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 234 citations

Medicine, Oncology, Pharmacology +16